Genmab — November 2017
-
-
Fra Novod "As mentioned above, Darzalex royalties reached DKK 253m in the quarter, which corresponds to a 12.6% royalty rate. Genmab also communicated that the royalty rate for Darzalex has moved to the next tier, which is at 13% for JnJ in-market sales above USD 750m. The peak royalty rate is 20% for sales exceeding USD 3bn, but we do not know the exact steps in between."
-
Beskos mener iflg et opslag på AP at Genmab skal ned i 700 herfra. Hvad siger I til det ?
-
Jeg tror at de fleste herinde husker, at Beskos i Børsen Play hævdede, at Genmab havde snydt med
forsøgsresultater. -
Både Genmab, undertegnede samt flere skribenter kontaktede Børsen. Indlægget blev derefter klippet ud.
-
Ja! Det er da rigtigt. Det havde jeg helt glemt
-
Han kender overhovedet ikke casen. Ved slet ikke hvad selskabets beskæftiger sig med.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind